MR Coordinating Committee Mark Rosen, MD PhD May 16, 2018 Topics - - PDF document

▶

Oct 19, 2023 180 likes •273 views

5/16/2018 MR Coordinating Committee Mark Rosen, MD PhD May 16, 2018 Topics of Discussion Change in composition of BCs and TFs; role of MR CC 1 5/16/2018 Meta-analysis Performed New BCs created from legacy PDF Meta-analysis Performed 2

SLIDE 1

5/16/2018 1

MR Coordinating Committee

Mark Rosen, MD PhD May 16, 2018

Topics of Discussion

Change in composition of BCs and TFs; role of MR CC

SLIDE 2

5/16/2018 2

Meta-analysis Performed Meta-analysis Performed

New BCs created from legacy PDF

SLIDE 3

5/16/2018 3

“Whole Body” metrics

Brain metrics

Liver metrics

Joint/MSK metrics Meta-analysis Performed

Augment MR CC… Leverage Areas of Specialization within MR CC

Topics of Discussion

Change in composition of BCs and TFs; role of MR CC
Plans for progression of BC activity beyond profiles

SLIDE 4

5/16/2018 4

Meta-analysis Performed

Progressing to Profiles…and Beyond …stopping point of some BC activity prior to claim/clinical confirmation

Topics of Discussion

Change in composition of BCs and TFs; role of MR CC
Plans for progression of BC activity beyond profiles
Challenges in anatomic specific vs. generic measurands

SLIDE 5

5/16/2018 5

“Whole Body” metrics

Brain metrics

Liver metrics

Joint/MSK metrics

DWI: brain claim DWI: liver claim DWI: prostate claim

Meta-analysis Performed

Topics of Discussion

Change in composition of BCs and TFs; role of MR CC
Plans for progression of BC activity beyond profiles
Challenges in anatomic specific vs. generic measurands
New biomarkers in MR?
Biomarkers vs. Phenotypes?
Multi-measurand imaging protocols (e.g liver, prostate, brain)
Role of radiomics

SLIDE 6

5/16/2018 6

“Whole Body” metrics

Brain metrics

Liver metrics

Joint/MSK metrics

CV T1  CV Ktrans

Meta-analysis Performed

CV T2*  CV PDFF fMRI(motor/language)  Resting state fMRI

Topics of Discussion

Change in composition of BCs and TFs; role of MR CC
Plans for progression of BC activity beyond profiles
Challenges in anatomic specific vs. generic measurands
New biomarkers in MR?
Biomarkers vs. Phenotypes?
Multi-measurand imaging protocols (e.g liver, prostate, brain)
Role of radiomics
Adapting profiles for technological advancements in MR

SLIDE 7

5/16/2018 7

Profiles v2.0 in MR

DCE: re-evaluate claims for modern imaging
3T and B1 heterogeneity
Groundwork project  challenge of B1 compensation
Effect of FOV: brain vs body imaging
Vendor-specific differences in B1 mapping protocols
 strong effect on VFA correlations

Profiles v2.0 in MR

Next generation of MR imaging
Multi-band excitation/parallel imaging/etc.
Need to recreate claim generation process (“from scratch”?)
Metrology concern: “bias creep” in using last methodology

as new ground truth

Liver examples: MRE and PDFF become the “gold standard”
FDA example: leveraging prior knowledge?

SLIDE 8

5/16/2018 8